Woman walks on the beach holding a scarf over her head.

INTERSTIM WITHOUT LIMITSTM

Your best choice for sacral neuromodulation.

PROVEN CHOICES

InterStim™ systems have been implanted in over 325,000 patients, and evaluated in more than 1,000 published clinical articles, including long-term (5-year) data for urinary incontinence, retention, and fecal incontinence.*

VIEW PRODUCTS
InterStim Micro systems which include a handheld device and InterStim Micro and InterStim II products for Sacral neuromodulation (SNM) uses mild electrical stimulation of the sacral nerve for bladder and bowel control.

HOW THE INTERSTIM™ SYSTEMS WORK

With the InterStim™ systems, the implanted neurostimulator and lead electrically stimulate the sacral nerve. This is thought to normalize neural communication between the bladder and brain and between the bowel and brain.1,2 Unlike oral medications that target the muscular component of bladder control, the InterStim™ systems offer control of symptoms through direct modulation of the nerve activity.1,2

One key advantage of this therapy is that it can be tested for potential success prior to implantation. The evaluation provides an opportunity to find out whether adequate symptom reduction is achieved in as few as three to seven days. Complications can occur with the evaluation, including tissue damage, infection, and technical problems with the device. Patients should be instructed on operating the programmer and given precautions related to the evaluation.

The most common adverse events experienced during clinical studies of patients with SNM included pain at implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations. Any of these may require additional surgery or cause return of symptoms.

FOR BLADDER CONTROL

  • Not all patients with bladder control problems benefit from standard medical therapy3,4
  • Standard pharmacological therapy for OAB consists of anticholinergics or β3- adrenoreceptor agonists, which are not effective for everyone5
  • More than 70% of patients stop taking OAB medications within six months due to side effects and/or lack of efficacy3
  • The InterStim™ II system can provide effective bladder control and proven efficacy for patients who do not find relief from initial treatments6,7 and the InterStim™ Micro system is designed to deliver the same results

 

FOR BOWEL CONTROL

  • Not all patients with bowel control problems benefit from medication, diet modification, and exercise8
  • The InterStim™ systems offer a minimally invasive option that can restore bowel function
  • The InterStim™ II system is effective, safe, and may offer patients improved quality of life9 and the InterStim™ Micro system is designed to deliver the same results

 

SHOW PATIENTS THE WAY

The Care Pathway helps patients envision their journey to relief, so they know what to expect and can keep moving forward.

LEARN MORE

SAY YES TO THE TEST

Learn the parameters of patient selection for bladder control and bowel control.

VIEW TOOLS

FOLLOW US ON TWITTER

Follow Medtronic Pelvic Health on Twitter for the latest updates on our products and therapies. 

FOLLOW US ON TWITTER

PATIENT MANAGEMENT WITHOUT LIMITS

Discover resources and support practices you can use to improve efficiency and find opportunities for growth.

SEE MARKETING TOOLS

PROGRAMMING

Download resources to guide programming decisions for the InterStim™ systems.

DOWNLOAD GUIDE

REIMBURSEMENT

Find details required to promote smooth prior authorization and reimbursement.

VIEW DETAILS

ONLINE EDUCATION

Take convenient courses specifically designed for clinicians treating patients with OAB, non-obstructive urinary retention and chronic fecal incontinence.

SEE COURSES
*

Data from InterStim Sales Analysis. Medtronic, Inc. April 2020.

Restored bladder function defined as ≥50% reduction in dysfunctional voiding symptoms from baseline. Restored bowel function is defined as ≥50% reduction in chronic fecal incontinence episodes.

1

Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. Urol Clin North Am. 2005;32:11-18.

2

Patton V, Wiklendt L, Arkwright JW, Lubowski DZ, Dinning PG. The effect of sacral nerve stimulation on distal colonic motility in patients with fecal incontinence. Br J Surg. 2013;100:959–968.

3

Yeaw J, Benner J, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):724-736.

4

Haab F, Castro-Diaz D. Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract. 2005;59(8):931-937.

5

Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. American Urological Association (AUA). J Urol. 2015 May;193(5):1572-80.

6

Noblett K, Siegel S, Mangel J, et al. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at 12 months in subjects with symptoms of OAB. Neurourol Urodyn. 2014. doi:10.1002/nau.22707.

7

Medtronic InterStim Therapy Clinical Summary, 2018.

8

Wald A, Bharucha AE, Cosman BC, et al. ACG clinical guideline: management of benign anorectal disorders. Am J Gastroenterol. 2014 Aug;109(8):1141-1157.

9

Hull T, Giese C, Wexner SD, Mellgren A, Devroede G, et al. Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. Dis Colon Rectum. 2013;56:234–245.